Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm

Nature Medicine

Volumn 3, Issue 3, 1997, Pages 324-327

  Miyagawa, Koichi ^a   Rösch, Josef ^b   Stanczyk, Frank ^c   Hermsmeyer, Kent ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; MEDROXYPROGESTERONE; PROGESTERONE; STEROID HORMONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; HORMONE SUBSTITUTION; ISCHEMIC HEART DISEASE; MONKEY; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VASOSPASM;

ANIMALS; CORONARY VASOSPASM; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; MACACA MULATTA; MEDROXYPROGESTERONE; OVARIECTOMY; PROGESTERONE; PROGESTERONE CONGENERS; RISK FACTORS;

ANIMALIA; MACACA MULATTA;

EID: 0031054234     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0397-324     Document Type: Article

References (23)

1. Gorodeski, G.I. & Utian, W.H. Epidemiology and risk factors of cardiovascular disease in postmenopausal women, in Treatment of the Postmenopausal Woman: Basic and Clinical Aspects (ed. Lobo, R.A.) 199-221 (Raven, New York, 1994).
2. Wenger, N.K., Speroff, L. & Packard, B. Cardiovascular health and disease in women. New Engl. J. Med. 329, 247-256 (1993).
3. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women, the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273, 199-208 (1995).
4. Lobo, R.A., Pickar, J.H., Wild, R.A., Walsh, B. & Hirvonen, E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in post-menopausal women. Obstet. Gynecol. 84, 987-995 (1994).
5. Poulter, N.R. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 346, 1575-1582 (1995).
6. Meirik, O. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346, 1582-1588 (1995).
7. Jick, H., Jick, S.S., Gurewich, V., Myers., M.W. & Vasilakis, C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346, 1589-1593 (1995).
8. Bloemenkamp, W.M., Rosendaal, F.R., Helmerhorst, F.M., Buller, H.R. & Vandenbrouke, J.P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346, 1593-1596 (1995).
9. Gilmore, J.P. Neural control of extracellular volume in the human and nonhuman primate, in Handbook of Physiology. Section 2: The Cardiovascular System, Vol. III, Part 2 (eds. Shepherd, J.T. & Abboud, F.M.) 885-915 (American Physiological Society, Baltimore, Maryland, 1983).
10. Adams, M.R., Washburn, S.A., Wagner, J.D., Williams, J.K. & Clarkson, T.B. Arterial changes: Estrogen deficiency and effects of hormone replacement, in Treatment of the Postmenopausal Woman: Basic and Clinical Aspects (ed. Lobo, R.A.) 243-250 (Raven, New York, 1994).
11. Hermsmeyer, K. et al. Reactivity-based coronary vasospasm independent of atherosclerosis in rhesus monkeys, J. Am. Coll. Cardiol. (in the press).
12. Williams, C.L. & Stancel, G.M. Estrogens and Progestins. in Goodman and Gilman's The Pharmacological Basis of Therapeutics (eds. Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W. & Gilman, A.G.) 1411-1440 (McGraw-Hill, New York, 1995).
13. Stanczyk, F.Z. Structure-function relationships, potency, and pharmacokinetics of progestogens. in Treatment of the Postmenopausal Woman: Basic and Clinical Aspects (ed. Lobo, R.A.) 69-89 (Raven, New York, 1994).
14. Resko, J.A., Ploem, J.G. & Stadelman, H.L. Estrogens in fetal and maternal plasma of the rhesus monkey. Endocrinology 98, 425-430 (1975).
15. 2+ in dog coronary arterial vascular muscle cells by Ro 40-5967. J. Cardiovasc. Pharmacol. 24, 1-7 (1994).
16. Maseri, A., Davies, G., Hackett, D. & Kaski, J.C. Coronary artery spasm and vasoconstriction. Circulation 81, 1983-1990 (1990).
17. Miller, V.M. & Vanhoutte, P.M. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am. J. Physiol. 261, R1022-R1027 (1991).
18. Slayden, O.D., Hirst, J.J. & Brenner, R.M. Estrogen action in the reproductive tract of rhesus monkeys during antiprogestin treatment. Endocrinology 132, 1845-1856 (1993).
19. Hiroi, M. et al. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration. Steroids 26, 373-386 (1975.)
20. Resko, J.A., Norman, R.L., Niswender, G.D. & Spies, H.G. The relationship between progesterone and gonadotropins during the late luteal phase of the menstrual cycle in rhesus monkeys. Endocrinology 94, 128-135 (1974).
21. Jiang, C.W., Sarrel, P.M., Lindsay, D.C., Poole-Wilson, P.A. & Collins, P. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur. J. Pharmacol. 211, 163-167 (1992).
22. Healy, B. PEPI in Perspective, good answers spawn pressing questions. JAMA 273, 240-241 (1995).
23. Belchetz, P.E. Hormonal treatment of postmenopausal women. New Engl. J. Med. 330, 1062-1071 (1994).